A Technology & Pipeline
Assessment and Corporate Benchmarking Analysis
The report “Recombinant Coagulation
Factors 2013 – The Race to Market and for Market Shares: Technology &
Pipeline Assessment and Corporate Benchmarking Analysis” of June 2013 describes
a market forecast based on growth of historical sales of recombinant
coagulation factors. The report evaluates reasons for failures of novel
recombinant coagulation factors and provides detailed profiles of active
recombinant coagulation factors in clinical development. Preclinical projects
are valued on the basis of the underlying technologies. Emerging alternative
therapeutic approaches are described and assessed.
To
Read The Complete Report with TOC : www.marketresearchreports.biz/analysis-details/recombinant-coagulation-factors-2013-the-race-to-market-and-for-market-shares-a-technology-and-pipeline-assessment-and-corporate-benchmarking-analysis
The detailed target pipeline
assessments put emphasis on the competitive situation regarding stage of
development, inhibitor profile, half-life, administration frequency, clinical
success and especially time to approval/market. The pipelines of the clinically
active companies are described and their competitive position assessed in light
of the key success factors. Sources of information are LMP’s proprietary
database, scientific literature (abstracts, papers), corporate information
(press releases, presentations, reports, SEC filings). All information is
referenced.
Combined product sales of the three
classes olf recombinant coagulation factors used in hemophilia were US$ 7.172
mln in 2012. The pipeline of new recombinant coagulation factors is maturing
and the first molecules are under regulatory review by the FDA and the EMA and
many have entered pivotal clinical studies. There are 46 different molecules
and R&D approaches for novel recombinant coagulation factors for hemophilia
A and B in the pipeline of which 24 are in clinical development of under
regulatory review. Given this tight competition, time-to-market will be an
important success. This report will explain the potential development and
approval timelines of each of the advanced molecules.
About
Us
MarketResearchReports.Biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs,
our main offerings are syndicated research reports, custom research,
subscription access and consulting services. We serve all sizes and types of
companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment